The article reports on the first approved GLP-1 pill, an Ipsen company looking for business opportunities, and other pharmaceutical news from Pharmalot.Online marketing of compounded GLP-1 drugs overemphasizes their benefits and understates their risks.An analysis published in JAMA Health Forum examined 79 websites selling compounded GLP-1 drugs or prescriptions for them.37% of these sites stated or implied that the drugs were FDA-approved.[Nearly half of the sites did not include information on side effects, warnings, and contraindications.2 In Connecticut, patients are seeking alternatives to GLP-1 drugs because of Medicaid restrictions on their coverage for obesity.[Some patients buy compounded versions for cash but mistake them for approved drugs, according to Reshma Ramachandran, M.D., of the Yale School of Medicine.The labs may be registered with the FDA, but the drugs themselves have not been tested beforehand.[2] The labs may be registered with the FDA, but the drugs themselves have not been tested.